# China NMPA Drug Inspection - Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd. - chrysanthemum

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-zhongmeitang-traditional-chinese-medicine-pieces-co-ltd/3b8d5aa2-31c8-4c86-a8b6-0d903513de5f/
Source feed: China

> China NMPA drug inspection for Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd. published April 20, 2017. Drug: chrysanthemum. The State Food and Drug Administration (SFDA) announced on April 20, 2017, the discovery of 33 batches of unqualified tr

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 59 of 2017 from the State Administration of Traditional Chinese Medicine regarding 33 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2017-04-20
- Drug Name: chrysanthemum
- Inspection Finding: Content determination and appearance were substandard.
- Action Taken: Control measures such as sealing and seizing have been taken, requiring the company to suspend sales and use, recall products, and rectify the situation; and an investigation has been launched into the illegal activities in accordance with the relevant provisions of the "Drug Administration Law of the People's Republic of China", with the results to be made public within three months.
- Summary: The State Food and Drug Administration (SFDA) announced on April 20, 2017, the discovery of 33 batches of unqualified traditional Chinese medicine (TCM) decoction pieces produced by 30 companies, including Kangmei Pharmaceutical Co., Ltd. Testing by the Anhui Provincial Institute for Food and Drug Control and the Hebei Provincial Institute for Drug Control revealed significant quality issues. Thirty-two batches of chrysanthemum from various manufacturers were found substandard regarding active component content determination and appearance (properties). Additionally, one batch of Forsythia suspensa from Beijing Yawei Traditional Chinese Medicine Pieces Co., Ltd. failed content determination tests. These violations indicate potential issues with ingredient quality, processing, or storage, impacting the efficacy and safety of the medicines. Operating under the "Drug Administration Law of the People's Republic of China" (Articles 73, 74, 75), provincial food and drug administrations initiated immediate control measures. These actions included sealing products, suspending sales and use, ordering recalls, and mandating rectifications. The SFDA further required thorough investigations into the production and sale of non-compliant drugs, demanding public disclosure of resolution within three months and severe penalties for confirmed manufacturers. Companies also maintain the right to object to product authenticity, triggering further verification. This announcement underscores the regulatory commitment to ensuring the quality and safety of traditional Chinese medicines.

Company: https://www.globalkeysolutions.net/companies/anhui-zhongmeitang-traditional-chinese-medicine-pieces-co-ltd/4a1dc5e0-b023-4d15-8511-24385790ddb3/